TVTX•businesswire•
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
Summary
SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)---- $TVTX #igan--CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy (IgAN), Kidney Disease: Improving Global Outcomes (KDIGO) 2025 clinical practice guideline for the management of IgA Nephropathy and Immunoglobulin A vasculitis. The updated guidelines define diagnostic criteria, treatment goals and treatment approaches, aiming for progress f
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 26, 2025 by businesswire